ABSTRACT:Studies have shown that in the rat, bisphenol A (BPA) is metabolized and eliminated primarily as a monoglucuronide, a metabolite without estrogenic activity. The purpose of this study was to determine the extent of monoglucuronide formation in monolayers of hepatocytes from rats, mice, and humans. Noncytotoxic concentrations of BPA (10, 20, and 35 M; 1.0 Ci), as assessed by lactate dehydrogenase leakage, were incubated with isolated hepatocytes for 0-6 h. Media were collected and analyzed for metabolites by radiochemical high performance liquid chromatography and liquid chromatography-tandem mass spectrometry. The metabolites identified include a monoglucuronide (major metabolite), a sulfate conjugate, and a glucuronide/sulfate diconjugate (minor metabolites). In hepatocytes of male Fischer-344 rats, the predominate metabolite was the diconjugate (glucuronide/sulfate). Under these conditions, the extent of metabolism by 3 h was similar in all species tested because all BPA was converted to conjugates by 3 h. Initial rates of metabolism in hepatocytes followed the order of mice > rats > humans. However, when extrapolated to the whole liver (i.e., cells per liver), the hepatic capacity for BPA glucuronidation is predicted to be humans > rats > mice. This research was supported in part by The Society of Plastics Industry Inc., and Southwest Environmental Health Science Center (ES 06694).Bisphenol A (BPA 1 ) is used in the production of polycarbonates, epoxy resins, phenolic resins, and diacrylates. Polycarbonates, one of the most widely used plastics, accounts for 60% of the total production of BPA (Perez et al., 1998). Epoxy-based resins are used in a variety of consumer products that include decorative floor manufacture, lacquer coatings in cans, dental composites and sealants, and as additives in the production of vinyl and acrylic resins. Trace amounts of BPA monomer have been reported to leach out of polycarbonate and epoxy resins (Brotons et al., 1995). Such leaching may result in the potential exposure of humans to trace amounts of BPA.Exposure to BPA is of interest, because it is known to possess weak estrogenic activity (Dodds and Lawson, 1936). In vitro it displaces estradiol from both the ␣ and  estrogen receptor and exhibits weak estrogenic activity (Krishnan et al., 1993, Kuiper et al., 1997. The binding of BPA to the estrogen receptor has been reported to be 10,000 times less than that of 17-estradiol (Gaido et al., 1997). Following oral exposure, BPA undergoes its first pass metabolism in the intestine and/or liver, which greatly limits its systemic bioavailability (Pottenger et al., 2000;Upmeier et al., 2000). In vitro data show that BPA is rapidly conjugated with glucuronic acid by hepatic rat microsomes (Yokota et al., 1999). Recent results obtained using rat hepatocytes (HC) or perfused liver confirm the extensive formation of a BPA monoglucuronide (Nakagawa and Tayama, 2000;Inoue et al., 2001) and correlate with in vivo findings that demonstrated the BPA-glucuronide to be the major me...
Purpose: Pancreatic ductal adenocarcinoma (PDAC) has the lowest five-year survival rate of all cancers in the United States. Programmed death 1 receptor (PD-1)-programmed death ligand 1 (PD-L1) immune checkpoint inhibition has been unsuccessful in clinical trials. Myeloid-derived suppressor cells (MDSCs) are known to block anti-tumor CD8+ T cell immune responses in various cancers including pancreas. This has led us to our objective that was to develop a clinically relevant in vitro organoid model to specifically target mechanisms that deplete MDSCs as a therapeutic strategy for PDAC. Method: Murine and human pancreatic ductal adenocarcinoma (PDAC) autologous organoid/immune cell co-cultures were used to test whether PDAC can be effectively treated with combinatorial therapy involving PD-1 inhibition and MDSC depletion. Results: Murine in vivo orthotopic and in vitro organoid/immune cell co-culture models demonstrated that polymorphonuclear (PMN)-MDSCs promoted tumor growth and suppressed cytotoxic T lymphocyte (CTL) proliferation, leading to diminished efficacy of checkpoint inhibition. Mouse- and human-derived organoid/immune cell co-cultures revealed that PD-L1-expressing organoids were unresponsive to nivolumab in vitro in the presence of PMN-MDSCs. Depletion of arginase 1-expressing PMN-MDSCs within these co-cultures rendered the organoids susceptible to anti-PD-1/PD-L1-induced cancer cell death. Conclusions: Here we use mouse- and human-derived autologous pancreatic cancer organoid/immune cell co-cultures to demonstrate that elevated infiltration of polymorphonuclear (PMN)-MDSCs within the PDAC tumor microenvironment inhibit T cell effector function, regardless of PD-1/PD-L1 inhibition. We present a pre-clinical model that may predict the efficacy of targeted therapies to improve the outcome of patients with this aggressive and otherwise unpredictable malignancy.
ABSTRACT:These studies characterize the effect of dose and route of administration on the disposition and elimination of the ionic liquid, 1-butyl-3-methylimidazolium chloride (Bmim-Cl). After i.v. (5 mg/ kg) or oral (50 mg/kg) administration to male F-344 rats [14 C]BmimCl detected in blood decreased rapidly. Clearance rates from the blood after i.v. and oral administration were similar (7.4 and 11.9 ml/min, respectively). Systemic bioavailability was determined to be 62.1% of a 50 mg/kg dose in rats. Urinary excretion of the parent compound by rats was the major route of elimination (i.v.: 91% in 24 h; oral: 55-74% in 24 h). The rates and routes of elimination were not affected by escalation of dose (0.5-50 mg/kg) or repeated oral administration (five daily administrations, 50 mg/kg) and were similar in male rats and B6C3F1 female mice (86-95% of dose eliminated in 24 h). Apparent systemic exposure to Bmim-Cl after dermal administration was dependent upon vehicle, as assessed by the percentage of dose eliminated in urine after application in a particular vehicle (water: 1%; ethanol/water: 3%; and dimethylformamide/water: 13% of dose). Regardless of gender, species, dose, route, or number of exposures, high-pressure liquid chromatography-UV/visible-radiometric analyses of urine samples showed a single peak that coeluted with the Bmim-Cl standard. These studies illustrate that systemic bioavailability of Bmim-Cl is high, tissue disposition and metabolism are negligible, and absorbed compound is extensively extracted by the kidney and eliminated in the urine as the parent compound.
Studies were conducted to characterize the metabolic and dispositional fate of (14)C-tetrabromobisphenol A (TBBPA)-a commonly used brominated flame retardant, in male Fischer-344 rats. The percent of dose eliminated as total radioactivity in feces at 72 h following three different single oral doses (2, 20, or 200 mg/kg) of (14)C-TBBPA was 90% or greater for all doses. Most of the dose was eliminated in the first 24 h. At 72 h after administration of the highest dose, the amounts of (14)C found in the tissues were minimal (0.2-0.9%). With repeated daily oral doses (20 mg/kg) for 5 or 10 days, the cumulative percent dose eliminated in the feces was 85.1+/-2.8 and 97.9+/-1.1, respectively. In all studies radioactivity recovered in urine was minimal, <2%. Repeated dosing did not lead to retention in tissues. Following iv administration, feces was also the major route of elimination. Following iv administration of TBBPA, the radiolabel found in the blood decreased rapidly and could be described by a biexponential equation, consistent with a two-compartment model. The key calculated kinetic parameters are terminal elimination half-life (t(1/2)beta)=82 min; area under the blood concentration-time curve from time 0 to infinity (AUC)=1440 mug x min/ml; and apparent clearance (CL)=2.44 ml/min. Although readily absorbed from the gut, systemic bioavailability of TBBPA is low (<2%). It is extensively extracted and metabolized by the liver and the metabolites (glucuronides) exported into the bile. About 50% of an oral dose (20 mg/kg) was found in the bile within 2 h. This extensive extraction and metabolism by the liver greatly limits exposure of internal tissues to TBBPA following oral exposures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.